Oscient reports cash, investments of $51 million at end of third quarter

By Lisa Kerner

Charlotte, N.C., Oct. 11 - Oscient Pharmaceuticals Corp. said it expects total cash, restricted cash and investments to total about $51 million for the quarter ended Sept. 30.

The Waltham, Mass., biopharmaceutical company used $12 million of its own cash toward the acquisition of Antara during the third quarter.

Oscient expects record total third-quarter revenues of slightly more than $11 million, with about $4 million from Antara 130 mg (fenofibrate) capsules.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.